沐舒坦不同用药途径对新生儿肺炎的白细胞、降钙素原及超敏C反应蛋白的影响分析  

Impacting Neonatal Pneumoni's Leukocytes, Procalcitonin and High-sensitivity C-reactive Protein with Different Route of Mucosolvan

作　　者：李婕[1] 

机构地区：[1]重庆医科大学附属第一医院产科,重庆400014

出　　处：《基因组学与应用生物学》2016年第5期1081-1087,共7页Genomics and Applied Biology

摘　　要：为研究沐舒坦不同用药途径对新生儿肺炎的白细胞、降钙素原及超敏C反应蛋白的影响,本研究选择2013年3月至2015年3月期间我院收治的74例新生儿肺炎患儿,按照随机数表法将74例患儿分为观察组(37例)和对照组(37例)。对照组为30 m L的生理盐水与7.5 mg的沐舒坦相吸收后予以静脉滴注。观察组患儿在对照组的基础上将生理盐水4 m L与沐舒坦15 mg制成雾化液后进行雾化吸入。观察两组患儿治疗前后外周血白细胞(white blood cell,WBC)、降钙素原(procalcitonin,PCT)及超敏C反应蛋白(highsensitivity C-reactive protein,Hs-CRP)、血气指标变化,比较两组患儿的临床疗效及住院时间与临床症状消失时间。治疗后,观察组患儿总的有效率94.59%(35/37)明显高于对照组78.38%(29/37)(p<0.05);观察组患儿的WBC(10.24±2.03)×109/L、PCT(0.82±0.14)μg/L、及Hs-CRP(1.02±0.25)mg/L水平要比对照组低(p<0.05);观察组患儿的Pa CO2(4.52±0.76)k Pa低于对照组(5.71±0.89)k Pa,Pa O2(13.07±2.54)高于对照组(10.86±1.69)k Pa(p<0.05);观察组患儿的住院时间(6.03±1.02)d明显短于对照组(9.24±2.33)d,临床症状消失时间也短于对照组(p<0.05)。由此得出结论,静脉滴注与雾化吸入沐舒坦相结合的方式治疗新生儿肺炎,能明显降低患儿的WBC、PCT、及Hs-CRP水平,可改善患儿的血气指标,其疗效良好,不良反应少,安全性高,为新生儿肺炎治疗提供新的治疗思路。To study the impact of neonatal pneumoni＇s leukocytes, procalcitonin, and high-sensitivity C-reactive protein with different route of mucosolvan, 74 children with neonatal pneumonia from March 2013 to March 2015 in our hospital were selected in this study. According to a random number table method, 74 patients were divided into two groups（37 patients） and control group（37 cases）. 37 patients in the control group, they were treated by 30 ml of normal saline and 7.5mg mucosolvan be absorbed after intravenous infusion phase. 37 children in the observation group, using 4ml made after Mucosolvan 15 mg liquid atomization inhalation on the basis of the control group. Peripheral blood leukocytes（white blood cell, WBC）, procalcitonin（Procalcitonin, PCT） and highsensitivity C-reactive protein（high-sensitivity C-reactive protein, Hs-CRP）, blood gas before and after treatment were observed. They were compared with the clinical efficacy and the length of stay hospital and time of clinical symptoms. After treatment, patients in the observation group total effective rate 94.59%（35/37） was significantly higher than control group 78.38%（29/37）（p〈0.05）. Observation group WBC（10.24±2.03）×109/L, PCT（0.82±0.14） μg/L, and Hs-CRP（1.02 ±0.25） mg/L level were lower than the control group（p〈0.05）. The observation group Pa CO2（4.52±0.76） k Pa lower than the control group（5.71±0.89） k Pa, Pa O2（13.07±2.54） was higher than thecontrol group（10.86 ±1.69） k Pa（p〈0.05）. Children hospitalized time of observation group（6.03 ±1.02） days was shorter than the control group（9.24±2.33） days, the symptoms disappeared time is shorter than the control group（p〈0.05）. The results showed that intravenous infusion and inhalation mucosolvan combination treatment of neonatal pneumonia, which can significantly reduce the WBC, PCT, and Hs-CRP levels in children, and can improve blood indicators of children, good efficacy, fewer side effects, safety,it offer new tr

关 键 词：沐舒坦 用药途径 肺炎 白细胞 降钙素原 超敏C反应蛋白 

分 类 号：R722.135[医药卫生—儿科]